Equine rabies immune globulin: a product with an undeserved poor reputation.

This research article discusses a study on the effectiveness and safety of equine rabies immune globulin (ERIG), specifically a product produced by Sclavo of Italy, in treating 419 patients exposed to rabies in Thailand. The results show that only a small percentage of patients experienced adverse reactions, with ERIG presenting a cost-effective alternative to human rabies immune globulin, especially in developing countries.

Research Purpose and Methodology

• The researchers set out to evaluate the effectiveness and suitability of equine rabies immune globulin, specifically a product made in Italy by Sclavo. This product is used in preventing rabies, a lethal viral infection that affects the nervous system in animals and humans.
• The study involved 419 patients in Thailand who were exposed to the rabies virus. They were treated with the ERIG product and monitored for a period of at least one month after the ERIG injection and rabies vaccine administration. Researchers were particularly interested in observing any adverse reactions to the treatment.

Research Findings

• The study observed adverse serum sickness-like reactions in about 3.58% of the patients (15 people). These reactions are typically characterized by symptoms like rashes, joint pain and fever, emulating a condition known as serum sickness.
• The reactions observed in the patients were clinically acceptable, implying they were neither extreme nor life-threatening. Only one patient out of the 15 required corticosteroid therapy and a brief hospital stay to manage the serum sickness.

Cost Effectiveness of ERIG

• A significant finding from the research is the cost effectiveness of ERIG compared to human rabies immune globulin (HRIG). ERIG is approximately one-tenth of the cost of HRIG, making it a more accessible option in developing countries where HRIG is typically not readily available.

Implications of the Research

• The researchers concluded that ERIG is a safe option for the prevention of rabies. It is underutilized and could be a crucial biological option in settings where HRIG is either unaffordable or unavailable.
• This study can build confidence in the usage of ERIG, helping to overcome its undeserved poor reputation, and advocate for its increased use, particularly in resource-limited settings where rabies is still a significant public health concern.